Anesthesia specific differences in a cardio-pulmonary resuscitation rat model; halothane versus sevoflurane

Esser, Torben; Keilhoff, Gerburg; Ebmeyer, Uwe

doi:10.1016/j.brainres.2016.10.003

Cited by 3 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a problem that should not be overlooked is that inhaled anesthetics exhibit liver toxicity. Halothane is the most commonly used drug that causes liver toxicity (22). Compared with halothane, the incidence of liver toxicity with sevoflurane, enflurane, isoflurane and other halogenated inhalation anesthetics is significantly decreased, but not completely eradicated (23).…”

Section: Discussionmentioning

confidence: 99%

Inhibition of SUMO2/3 antagonizes isoflurane‑induced cancer‑promoting effect in hepatocellular carcinoma Hep3B cells

et al. 2021

View full text Add to dashboard Cite

Surgery for patients with complicated liver cancer often results in a long exposure to anesthesia with an increase in side effects. Continued long-term exposure to isoflurane may promote liver cancer progression. Small ubiquitin-like modifier (SUMO) 2 and 3, also known as SUMO2/3, conjugates to substrate proteins when cells undergo acute stress. However, whether or not SUMO2/3 is involved in isoflurane-mediated liver cancer progression is unknown. In the present study, hepatocellular carcinoma (HCC) cells were exposed to 2% isoflurane for 12 h, followed by 36 h of drug withdrawal, and the formation of SUMO2/3 conjugates and cancer behavioral characteristics were studied. The results demonstrated that the formation of SUMO2/3 conjugates was significantly increased following HCC cells being exposed to isoflurane for 0.5 h, and continued to increase for 48 h, even after the drug had been withdrawn. Furthermore, isoflurane-exposed HCC cells exhibited increased proliferation and invasion activity during the subsequent observation period. SUMO specific protease 3 (SENP3), which inhibits the binding of SUMO2/3 to its target proteins, was overexpressed and it was discovered that isoflurane-induced SUMOylation was significantly inhibited, and accordingly, the proliferation and invasion abilities of HCC cells were decreased to a certain extent. These findings indicated that SUMO2/3 is involved in the progression of HCC cells, at least in the Hep3B cell line, induced by the anesthetic isoflurane, and that inhibition of SUMO2/3 may antagonize the response. These results provided a novel target for decreasing the adverse reactions occurring in patients with HCC during anesthesia, particularly those who are exposed to isoflurane for long periods of time.

show abstract

Section: Discussionmentioning

confidence: 99%

Inhibition of SUMO2/3 antagonizes isoflurane‑induced cancer‑promoting effect in hepatocellular carcinoma Hep3B cells

et al. 2021

View full text Add to dashboard Cite

show abstract

“…We observed significant clinical heterogeneity across the included study populations that limits generalizability, although this did not necessarily translate into statistical heterogeneity in our analysis. There also was variability in choice of both volatile and conventional sedation agents across studies, which is an important consideration given that experimental models of cardiac arrest have shown differing neurological outcomes with the use of various intravenous sedation agents (39) as well as different volatile agents (40). Two of our papers (22,23) included propofol as the primary conventional sedation agent, whereas the analysis by Krannich et al (21) used a combination of fentanyl and midazolam-which both have significantly longer offset time than propofol.…”

Section: Discussionmentioning

confidence: 99%